Cytek Biosciences (CTKB) Set to Post Quarterly Earnings on Wednesday

Key Points

• Cytek Biosciences is expected to report Q3 2026 results after Wednesday’s market close. Analysts forecast a loss of $0.07 per share and revenue of $53.05 million; the earnings call is scheduled for 4:30 p.m. ET.
• In the prior quarter, Cytek reported a $0.09-per-share loss in line with estimates and revenue of $48.14 million, exceeding expectations of $47.31 million. Analysts project full-year and next-year losses of $0.36 and $0.32 per share, respectively.
• CTKB shares opened at $5.98, near their 52-week high of $6.21, while analysts maintain a consensus “Hold” rating and an average price target of $5.88.

Cytek Biosciences (NASDAQ:CTKB - Get Free Report) is expected to be announcing its Q3 2026 results after the market closes on Wednesday, November 4th. Analysts expect Cytek Biosciences to post earnings of ($0.07) per share and revenue of $53.05 million for the quarter. Investors can find conference call details on the company's upcoming Q3 2026 earnings results page for the latest details on the call scheduled for Wednesday, November 4, 2026 at 4:30 PM ET.

Cytek Biosciences (NASDAQ:CTKB - Get Free Report) last announced its quarterly earnings data on Wednesday, August 5th. The company reported ($0.09) earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of ($0.09). The firm had revenue of $48.14 million during the quarter, compared to analysts' expectations of $47.31 million. On average, analysts expect Cytek Biosciences to post ($0.36) EPS for the current fiscal year and ($0.32) EPS for the next fiscal year.

Cytek Biosciences Stock Performance

CTKB opened at $5.98 on Wednesday. Cytek Biosciences has a fifty-two week low of $3.31 and a fifty-two week high of $6.21. The firm's fifty day moving average is $5.19 and its 200 day moving average is $4.65. The stock has a market cap of $777.30 million, a price-to-earnings ratio of -9.65 and a beta of 1.16.

Wall Street Analyst Weigh In

A number of equities analysts have recently weighed in on CTKB shares. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Cytek Biosciences in a research note on Monday, September 21st. Stephens reissued an "overweight" rating and set a $6.00 target price on shares of Cytek Biosciences in a research note on Friday. Finally, Morgan Stanley set a $5.00 price target on Cytek Biosciences in a report on Friday, August 7th. Three analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat, Cytek Biosciences has an average rating of "Hold" and a consensus price target of $5.88.

Cytek Biosciences Company Profile

Cytek Biosciences, Inc develops and commercializes cell analysis solutions for biomedical research, clinical research and biopharmaceutical applications. The company focuses on spectral flow cytometry, a technology that enables researchers to analyze multiple characteristics of individual cells and identify complex cell populations.

Its product portfolio includes the Aurora and Northern Lights spectral flow cytometers, compact and specialized instruments, cell sorters, software and a range of fluorescent reagents.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.